Richard C. Shelton, MD

  • 59Articles
  • 207.5KReads1
  • 1997–2025Active
  • 203Collaborators
  • 686Citations2

About

Richard C. Shelton, MD, is affiliated with the Department of Psychiatry and Behavioral Neurobiology at the University of Alabama at Birmingham. With a publication record spanning from 1997 to 2025, Shelton has contributed extensively to research on major depressive disorder, treatment-resistant depression, bipolar disorder, schizophrenia and schizoaffective disorders, anxiety, addiction, cognition, and mood disorders. His work includes clinical trials investigating novel pharmacologic agents, augmentation strategies, pharmacogenomics, and predictors of treatment outcomes. Shelton has frequently collaborated with noted researchers such as Maurizio Fava, Madhukar H. Trivedi, and George I. Papakostas.

Publications

JCP
BI 1358894 in Patients With Inadequate Antidepressant Response
Original Research

BI 1358894 in Patients With Inadequate Antidepressant Response

September 3, 2025

No differences were observed between BI 1358894 treatment groups and placebo for primary and secondary endpoints. BI 1358894 was well tolerated with no increase in self-harm or suicidality.
, , , et al
JCP
Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life
Original Research

Effect of Aripiprazole or rTMS Augmentation Versus Switching to Venlafaxine on Quality of Life

August 11, 2025

Augmentation with aripiprazole, but not rTMS, improved quality of life significantly versus venlafaxine XR/duloxetine switch in patients with treatment-resistant depression.
, , , et al
JCP
Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study
Original Research

Onfasprodil (MIJ821) in Patients with Treatment-Resistant Depression: A Phase 2, Randomized, Placebo-Controlled, Proof-of-Concept Study

August 6, 2025

Onfasprodil appeared to be effective and well-tolerated across all dosing regimens in patients with TRD and demonstrated rapid onset of action (24 hours) with evidence of antidepressant effects to...
, , , et al
JCP
Original Research

Adjunctive Pimavanserin and Sleep/Wakefulness in MDD

December 1, 2020

Adjunctive pimavanserin can reduce depressive symptoms and improve function in patients with major depression and inadequate antidepressant response. This analysis evaluated the effects of adjunctive pimavanserin on sleep/wakefulness disturbances.
, , , et al
JCP
Original Research

Utility of Combinatorial Pharmacogenomics in Depression

October 31, 2019

This study sought to ascertain the extent that pharmacogenetic testing can inform treatment decisions among patients with treatment-resistant depression whose medications are subject to gene-drug interactions—read the article to...
, , , et al
JCP
Original Research

Adjunctive Pimavanserin in Treatment-Resistant MDD

September 24, 2019

The use of atypical antipsychotics as adjunctive treatment for nonresponsive depression is limited by their side effects. This study explores whether pimavanserin can be both an efficacious and tolerable...
, , , et al
JCP
Original Research

Delayed Remission After Antidepressant Treatment

November 21, 2017

Will physicians soon be able to predict which patients will experience delayed response to antidepressant treatment so that they can direct them to potentially more effective treatments? Read this...
, ,
JCP
Original Research

Ziprasidone Augmentation of Escitalopram for Cognition

July 25, 2017

Cognitive deficits are common in depression, but studies suggest that cognitive dysfunction is difficult to treat with antidepressants. Can adding an atypical antipsychotic medication to antidepressant treatment help lessen...
, , , et al
JCP
Original Research

Secondary Effects of Ziprasidone Augmentation in MDD

April 26, 2017

The atypical antipsychotic ziprasidone is effective in depressed patients who don' t respond to antidepressants, but is it safe? Learn about the clinical relevance of possible cardiac, metabolic, and...
, , , et al
JCP
Original Research

Long-Term Efficacy, Safety, and Tolerability of l-Methylfolate Calcium 15 mg as Adjunctive Therapy With Selective Serotonin Reuptake Inhibitors: A 12-Month, Open-Label Study Following a Placebo-Controlled #05#

May 25, 2016

, , , et al
JCP
Original Research

Baseline Disability and Poor Functioning in Bipolar Disorder Predict Worse Outcomes: Results From the Bipolar CHOICE Study

January 27, 2016

, , , et al
JCP
Original Research

Bipolar CHOICE (Clinical Health Outcomes Initiative in Comparative Effectiveness): A Pragmatic 6-Month Trial of Lithium Versus Quetiapine for Bipolar Disorder

January 27, 2016

, , , et al

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Insightful. Evidence-based. Human-centered.

Listen Now
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe